Igor Bilinsky
Chief Operating Officer bij IOVANCE BIOTHERAPEUTICS, INC.
Vermogen: 582 958 $ op 29-02-2024
Profiel
Igor P. Bilinsky bekleedt de functie van Chief Operating Officer bij Iovance Biotherapeutics, Inc. Dr. Bilinsky bekleedde voorheen de functie van Chief Executive Officer bij Androclus Therapeutics, Inc., VP-Business Development & Special Operations bij Halozyme Therapeutics, Inc., Principal bij The Boston Consulting Group, Inc., Chief Business Officer voor Oncternal Therapeutics, Inc, Chief Operating Officer & Senior Vice President van AmpliPhi Biosciences Corp., Head-Research & Development bij Symyx Technologies, Inc., Senior Vice President-Corporate Development voor Vical, Inc. en Senior VP-Special Operations, GM-Immuno & Oncology bij Ignyta, Inc. Igor P. Bilinsky behaalde een doctoraat aan het Instituut voor Natuurkunde en Technologie van Moskou en een doctoraat aan het Massachusetts Institute of Technology.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
04-03-2024 | 36 641 ( 0.01% ) | 582 958 $ | 29-02-2024 |
Actieve functies van Igor Bilinsky
Bedrijven | Functie | Begin |
---|---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Chief Operating Officer | 15-03-2021 |
Eerdere bekende functies van Igor Bilinsky
Bedrijven | Functie | Einde |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Corporate Officer/Principal | 01-03-2021 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Operating Officer | 14-01-2019 |
IGNYTA INC | Corporate Officer/Principal | 01-01-2017 |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2010 |
Androclus Therapeutics, Inc. | Chief Executive Officer | 01-01-2007 |
Opleiding van Igor Bilinsky
Massachusetts Institute of Technology | Doctorate Degree |
Moscow Institute of Physics & Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Androclus Therapeutics, Inc. | |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |